Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

EFTR

eFFECTOR Therapeutics Inc

May 03 • 04:00PM ET

2.20

Dollar change +0.04
Percentage change 1.85	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-7.19	Insider Own	7.43%	Shs Outstand	4.70M	Perf Week	16.40%
Market Cap	10.34M	Forward P/E	-	EPS next Y	-2.03	Insider Trans	-63.56%	Shs Float	4.35M	Perf Month	-25.68%
Income	-35.81M	PEG	-	EPS next Q	-2.17	Inst Own	6.18%	Short Float	5.61%	Perf Quarter	-79.17%
Sales	0.00M	P/S	-	EPS this Y	68.39%	Inst Trans	-60.62%	Short Ratio	0.63	Perf Half Y	-83.63%
Book/sh	-1.94	P/B	-	EPS next Y	60.77%	ROA	-144.33%	Short Interest	0.24M	Perf Year	-82.04%
Cash/sh	3.91	P/C	0.56	EPS next 5Y	-	ROE	-946.56%	52W Range	1.60 - 37.00	Perf YTD	-81.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.64%	ROI	-	52W High	-94.05%	Beta	0.93
Dividend TTM	-	Quick Ratio	0.77	Sales past 5Y	-40.00%	Gross Margin	84.00%	52W Low	37.50%	ATR (14)	0.68
Dividend Ex-Date	-	Current Ratio	0.77	EPS Y/Y TTM	-24.91%	Oper. Margin	0.00%	RSI (14)	31.82	Volatility	9.52% 11.11%
Employees	14	Debt/Eq	-	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	65.67
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-1434.65%	Payout	-	Rel Volume	0.38	Prev Close	2.16
Sales Surprise	-	EPS Surprise	-21.28%	Sales Q/Q	-100.00%	Earnings	Mar 25 AMC	Avg Volume	385.93K	Price	2.20
SMA20	7.67%	SMA50	-74.52%	SMA200	-82.65%	Trades		Volume	144,737	Change	1.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-22	Downgrade	Stifel	Buy → Hold	$20 → $6.20
Nov-09-21	Upgrade	Stifel	Hold → Buy	$20
Oct-12-21	Initiated	Credit Suisse	Outperform	$20
Oct-04-21	Initiated	Mizuho	Buy	$20
Sep-21-21	Initiated	JMP Securities	Mkt Outperform	$33
Sep-20-21	Initiated	Stifel	Hold	$20
Sep-13-21	Initiated	Cantor Fitzgerald	Overweight	$50

Apr-09-24 08:00AM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conference (GlobeNewswire) +8.45%
Apr-05-24 12:58PM	eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails (Zacks) -15.20%
Apr-04-24 08:30AM	eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer (GlobeNewswire) -82.03%
Mar-25-24 09:53PM	EFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +11.60%
04:01PM	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:30AM	Loading…
Feb-05-24 08:30AM	eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-24 09:55AM	Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect? (Zacks)
Jan-29-24 04:05PM	eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +10.90%
Jan-25-24 08:00AM	eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -8.74%
Jan-09-24 08:05AM	eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024 (GlobeNewswire) -19.87%
08:00AM	eFFECTOR Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Dec-08-23 08:15AM	eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients (GlobeNewswire) -9.02%
Nov-28-23 08:00AM	eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer (GlobeNewswire)
Nov-15-23 08:00AM	eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting (GlobeNewswire)
Nov-13-23 04:14PM	eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.42%
08:00AM	Loading…
Nov-06-23 08:00AM	eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference (GlobeNewswire) +5.44%
Oct-24-23 08:00AM	eFFECTOR Therapeutics to Collaborate with the Northwestern University Division of Hematology and Oncology on an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Acute Myeloid Leukemia (GlobeNewswire)
Sep-11-23 08:00AM	eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors (GlobeNewswire)
Aug-30-23 08:00AM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-11-23 06:05AM	eFFECTOR Therapeutics First Half 2023 Earnings: US$0.41 loss per share (vs US$0.093 loss in 1H 2022) (Simply Wall St.)
Aug-08-23 04:01PM	eFFECTOR Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-08-23 04:01PM	eFFECTOR Therapeutics Raises a Total of $16.2 Million in Gross Proceeds from Two Recent Registered Direct Offerings (GlobeNewswire)
Jun-07-23 08:00AM	eFFECTOR Therapeutics Announces $8.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -7.19%
May-31-23 05:43PM	eFFECTOR Therapeutics Announces Closing of $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +12.97%
May-26-23 09:00AM	eFFECTOR Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +24.76%
May-25-23 04:50PM	eFFECTOR Therapeutics Reports Positive Data Updates from Phase 2 Expansion Cohorts Evaluating Zotatifin in Patients with ER+ Metastatic Breast Cancer at the ASCO 2023 Annual Meeting (GlobeNewswire) -23.83%
May-09-23 04:01PM	eFFECTOR Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 08:00AM	eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference (GlobeNewswire) +10.34%
Apr-26-23 04:01PM	eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual Meeting (GlobeNewswire) -8.78%
Apr-11-23 08:00AM	eFFECTOR Therapeutics to Collaborate with Stanford Medicine on Investigator-Initiated Randomized Phase 2 Study in Patients with ER+ Breast Cancer (GlobeNewswire) +7.28%
08:30AM	Loading…
Mar-28-23 08:30AM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-08-23 04:01PM	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.15%
Feb-21-23 08:30AM	eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID (GlobeNewswire) -18.09%
Jan-30-23 08:00AM	eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference (GlobeNewswire)
Jan-05-23 04:01PM	eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update (GlobeNewswire) -17.67%
Nov-07-22 04:00PM	eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.53%
Oct-31-22 02:05PM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-26-22 08:00AM	eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 (GlobeNewswire)
Sep-26-22 08:00AM	eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer (GlobeNewswire)
Sep-21-22 09:00AM	eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference (GlobeNewswire)
Sep-14-22 08:00AM	eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19 (GlobeNewswire)
Sep-06-22 08:30AM	eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-09-22 04:01PM	eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -27.35%
Aug-08-22 05:30AM	eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer (GlobeNewswire) +9.30%
Jun-07-22 08:00AM	eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference (GlobeNewswire) -6.47%
Jun-05-22 05:00PM	eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity (GlobeNewswire)
May-26-22 05:15PM	eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting (GlobeNewswire)
May-10-22 04:02PM	eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 06:45AM	How Much Of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Do Institutions Own? (Simply Wall St.)
May-02-22 04:04PM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -11.11%
Apr-04-22 08:30AM	eFFECTOR Therapeutics Announces Transition in Clinical Leadership (GlobeNewswire)
Mar-16-22 04:01PM	eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-16-22 08:30AM	eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors (GlobeNewswire)
Feb-15-22 06:53PM	2 Strong Buy Stocks That Could Be Bought Out, According to Credit Suisse (TipRanks)
Feb-09-22 04:00PM	eFFECTOR Therapeutics to Present at 2022 BIO CEO & Investor Conference (GlobeNewswire)
Jan-24-22 04:00PM	eFFECTOR Therapeutics Provides Pipeline and Business Updates (GlobeNewswire) -6.07%
Nov-24-21 08:00AM	eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology (GlobeNewswire)
Nov-22-21 08:00AM	eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit (GlobeNewswire)
Nov-08-21 07:00AM	eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +6.21%
Nov-04-21 09:08AM	Do Institutions Own eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Shares? (Simply Wall St.)
Nov-01-21 04:05PM	eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors (GlobeNewswire)
Oct-26-21 08:00AM	eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-07-21 04:30PM	Baylor College of Medicine Presents eFFECTOR Therapeutics-Backed Preclinical Data Supporting Development of Zotatifin in Triple-Negative Breast Cancer at 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-30-21 04:32PM	Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-16-21 08:00AM	eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference (GlobeNewswire) +5.84%

eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). Its STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase 1/2 (MNK 1/2). The company was founded by Kevan Shokat, Davide Ruggero, and Siegfried Reich on May 1, 2012 and is headquartered in Solana Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Nov 27 '23	Sale	0.61	609,163	369,457	1,821,415	Nov 29 05:07 PM
WORLAND STEPHEN T	Chief Executive Officer	Aug 11 '23	Option Exercise	0.52	33,799	17,575	261,225	Aug 14 08:00 AM

Open in Screener

ACLX

Arcellx Inc

May 03 • 04:00PM ET

52.69

Dollar change -0.60
Percentage change -1.13	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO IBB VTWO SCHA VHT LABU IDNA

Index	RUT	P/E	-	EPS (ttm)	-1.51	Insider Own	25.35%	Shs Outstand	52.28M	Perf Week	1.48%
Market Cap	2.81B	Forward P/E	-	EPS next Y	-1.91	Insider Trans	-8.99%	Shs Float	39.78M	Perf Month	-15.03%
Income	-70.69M	PEG	-	EPS next Q	-0.51	Inst Own	73.96%	Short Float	10.12%	Perf Quarter	-17.08%
Sales	110.32M	P/S	25.45	EPS this Y	-26.34%	Inst Trans	15.29%	Short Ratio	8.79	Perf Half Y	53.21%
Book/sh	9.28	P/B	5.68	EPS next Y	-2.70%	ROA	-12.41%	Short Interest	4.03M	Perf Year	21.18%
Cash/sh	13.21	P/C	3.99	EPS next 5Y	-	ROE	-20.48%	52W Range	30.74 - 75.10	Perf YTD	-5.06%
Dividend Est.	-	P/FCF	15.08	EPS past 5Y	-29.89%	ROI	-13.18%	52W High	-29.84%	Beta	0.24
Dividend TTM	-	Quick Ratio	6.06	Sales past 5Y	0.00%	Gross Margin	97.64%	52W Low	71.41%	ATR (14)	2.75
Dividend Ex-Date	-	Current Ratio	6.06	EPS Y/Y TTM	65.88%	Oper. Margin	-81.47%	RSI (14)	38.89	Volatility	5.35% 4.68%
Employees	130	Debt/Eq	0.20	Sales Y/Y TTM	-	Profit Margin	-64.08%	Recom	1.13	Target Price	80.31
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	142.94%	Payout	-	Rel Volume	0.87	Prev Close	53.29
Sales Surprise	214.47%	EPS Surprise	178.87%	Sales Q/Q	-	Earnings	Feb 28 AMC	Avg Volume	457.98K	Price	52.69
SMA20	-4.36%	SMA50	-16.40%	SMA200	6.70%	Trades		Volume	397,801	Change	-1.13%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-24	Initiated	Morgan Stanley	Overweight	$81
Jan-04-24	Reiterated	Needham	Buy	$65 → $71
Dec-19-23	Initiated	Scotiabank	Sector Outperform	$66
Oct-30-23	Initiated	TD Cowen	Outperform
Oct-17-23	Initiated	UBS	Buy	$52
May-18-23	Initiated	Truist	Buy	$60
Apr-14-23	Initiated	Robert W. Baird	Outperform	$39
Mar-14-23	Initiated	Stifel	Buy	$43
Feb-13-23	Initiated	H.C. Wainwright	Buy	$42
Dec-13-22	Resumed	BofA Securities	Buy	$29 → $37
Oct-31-22	Initiated	Guggenheim	Buy	$36
Oct-27-22	Initiated	Needham	Buy	$31
Jul-20-22	Initiated	Canaccord Genuity	Buy	$32
Mar-01-22	Initiated	SVB Leerink	Outperform	$47
Mar-01-22	Initiated	BofA Securities	Buy	$24

Show Previous Ratings

May-03-24 05:57PM	Arcellx Insider Sold Shares Worth $932,557, According to a Recent SEC Filing (MT Newswires)
Apr-23-24 11:26AM	Should You Be Bullish on Arcellx (ACLX)? (Insider Monkey)
Apr-04-24 04:00PM	Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
08:40AM	How Arcellx (ACLX) Stock Stands Out in a Strong Industry (Zacks)
Mar-29-24 02:57PM	Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
08:13AM	Loading…
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
Mar-27-24 01:50AM	Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares (GuruFocus.com)
Mar-20-24 04:00PM	Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (Business Wire)
Feb-29-24 04:00PM	Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference (PR Newswire)
Feb-28-24 07:30PM	Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates (Zacks)
04:00PM	Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights (PR Newswire)
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Jan-16-24 01:51PM	Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market (InvestorPlace)
Dec-22-23 01:30AM	Chief Medical Officer Christopher Heery Sells 120,000 Shares of Arcellx Inc (GuruFocus.com)
Dec-15-23 05:04PM	Pharmas Frontline: 3 Stocks Driving Revolutionary Drug Development (InvestorPlace)
04:00PM	Loading…
Dec-08-23 04:00PM	Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH (PR Newswire)
Nov-30-23 09:37PM	3 Biotech Stocks That Could Be Multibaggers in the Making (InvestorPlace)
Nov-21-23 08:00AM	These Stocks Are Exploding In The November Stock Market Rally (Investor's Business Daily)
Nov-16-23 10:10AM	Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead (Zacks)
Nov-15-23 04:05PM	Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead (Investor's Business Daily) +5.31%
09:47AM	Arcellx Stock Surges as Gilead Adds to Stake, Expands Collaboration (Barrons.com)
09:22AM	Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market (FierceBiotech.com)
07:16AM	Gilead expands Arcellx cancer cell therapy deal (BioPharma Dive)
06:00AM	Kite and Arcellx Announce Expansion in Strategic Partnership (Business Wire)
06:00AM	ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP (PR Newswire)
Nov-13-23 04:47PM	Arcellx Inc (ACLX) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:00PM	Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights (PR Newswire)
Nov-09-23 11:14AM	There Were 181 IPOs In 2022: $1K In Either Of These Two Would Have You Up 200%+ (Benzinga)
08:30AM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Nov-02-23 09:40AM	Are Medical Stocks Lagging Arcellx (ACLX) This Year? (Zacks) +18.55%
09:00AM	Loading…
09:00AM	Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition (PR Newswire)
Oct-26-23 04:00PM	Arcellx to Participate in Two Upcoming Investor Conferences (PR Newswire)
Oct-23-23 02:50AM	7 Biotech Stocks to Get In Now Before Investors Catch On (InvestorPlace)
Oct-17-23 09:40AM	Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-04-23 09:55AM	Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade (Zacks)
Sep-01-23 09:18AM	5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects (Zacks)
Aug-17-23 09:55AM	Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect? (Zacks)
Aug-16-23 01:21PM	Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies (Zacks)
Aug-14-23 04:00PM	Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results (PR Newswire)
Jul-31-23 07:13AM	Arcellx's (NASDAQ:ACLX) investors will be pleased with their respectable 51% return over the last year (Simply Wall St.)
Jul-25-23 02:37AM	Should You be Bullish on Arcellx (ACLX)? (Insider Monkey)
Jun-26-23 12:48PM	Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion (Zacks)
Jun-22-23 11:04AM	Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More (Zacks)
Jun-21-23 10:38AM	Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA (Zacks)
Jun-20-23 04:05PM	Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death (Investor's Business Daily) -7.18%
Jun-19-23 07:46PM	Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program (PR Newswire)
May-11-23 10:45AM	Top Small-Cap Stocks for May 2023 (Investopedia)
May-10-23 06:11AM	Results: Arcellx, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts (Simply Wall St.)
May-08-23 05:15PM	Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:00PM	Arcellx Provides First Quarter Financial Results (PR Newswire)
May-04-23 04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
Apr-28-23 03:34PM	Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript (Motley Fool)
Apr-25-23 12:00PM	Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy? (Zacks)
Apr-21-23 12:00PM	Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.50%
Apr-13-23 04:01PM	Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (PR Newswire)
Apr-11-23 10:00AM	Best Momentum Stocks to Buy for April 11th (Zacks)
Apr-05-23 09:55AM	Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know (Zacks)
Apr-04-23 12:20PM	Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy? (Zacks)
Apr-03-23 08:34AM	Do Options Traders Know Something About Arcellx (ACLX) Stock We Don't? (Zacks)
Mar-29-23 05:25PM	Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights (PR Newswire)
Mar-16-23 12:18PM	Is a Surprise Coming for Arcellx (ACLX) This Earnings Season? (Zacks)
Feb-21-23 04:00PM	Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference (PR Newswire) -5.09%
Feb-02-23 04:00PM	Arcellx to Participate in Upcoming Investor Conferences (PR Newswire)
Jan-30-23 09:00AM	Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma (Business Wire)
Jan-04-23 11:45AM	Gilead's (GILD) Application for Trodelvy Gets EMA Validation (Zacks)
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-12-22 10:55AM	Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology (Zacks)
Dec-09-22 04:08PM	Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences (Investor's Business Daily) +29.24%
09:54AM	Arcellx Stock Surges on Multiple Myeloma Treatment Collaboration With Gilead (Barrons.com)
09:42AM	Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate (Benzinga)
08:46AM	Gilead to co-develop Arcellx's multiple myeloma drug (MarketWatch)
08:17AM	Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma (Business Wire)
08:17AM	Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress (PR Newswire)
08:15AM	Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma (PR Newswire)
Nov-30-22 11:08AM	We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely (Simply Wall St.)
Nov-14-22 04:00PM	Arcellx Reports Third Quarter 2022 Financial Results and Business Progress (PR Newswire)
01:13PM	The bear market rally has more room to run, Guggenheim says. Here are 2 stocks to bet on (TipRanks)
Oct-27-22 02:37PM	Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock (Benzinga)
Sep-08-22 09:55AM	Wall Street Analysts Think Arcellx, Inc. (ACLX) Could Surge 62%: Read This Before Placing a Bet (Zacks)
Aug-15-22 04:00PM	Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial Results (PR Newswire)
Aug-01-22 08:00AM	Gaithersburg biotech inks deal for Rockville expansion as two more office buildings are converted to lab space (American City Business Journals) +6.32%
Jun-23-22 10:50AM	We're Hopeful That Arcellx (NASDAQ:ACLX) Will Use Its Cash Wisely (Simply Wall St.) +7.89%
Jun-21-22 04:05PM	Arcellx Announces Appointment of Maryam Abdul-Kareem as General Counsel (PR Newswire)
04:01PM	Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares (PR Newswire)
Jun-15-22 10:47PM	Arcellx Announces Upsizing and Pricing of Follow-On Public Offering (PR Newswire)
Jun-10-22 05:00PM	ASCO 2022: Surprising News in Cancer Research (Motley Fool) +16.39%
Jun-06-22 04:09PM	How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer (Investor's Business Daily) +20.63%
Jun-03-22 04:00PM	Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting (PR Newswire)
May-27-22 09:57AM	Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting (MarketWatch) +20.56%
May-23-22 04:05PM	Arcellx Appoints Michelle Gilson as Chief Financial Officer (PR Newswire) +11.03%
May-16-22 04:01PM	Arcellx Appoints Olivia Ware to Board of Directors (PR Newswire) -14.59%
May-12-22 04:01PM	Arcellx Provides Business Updates and Reports First Quarter 2022 Financial Results (PR Newswire)
May-10-22 04:01PM	Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma (PR Newswire) +13.60%
May-09-22 04:01PM	Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma (PR Newswire) -7.28%
10:00AM	Here's What Arcellx, Inc.'s (NASDAQ:ACLX) Shareholder Ownership Structure Looks Like (Simply Wall St.)
May-05-22 04:01PM	Arcellx Announces Participation at the BofA Securities 2022 Healthcare Conference (PR Newswire)
Apr-27-22 10:00AM	Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heery Christopher	CHIEF MEDICAL OFFICER	May 01 '24	Option Exercise	6.28	18,168	114,095	27,106	May 03 05:50 PM
Heery Christopher	CHIEF MEDICAL OFFICER	May 01 '24	Sale	51.33	18,168	932,557	8,938	May 03 05:50 PM
Ware Olivia C	Director	Apr 16 '24	Option Exercise	7.61	9,402	71,549	9,402	Apr 18 04:01 PM
Ware Olivia C	Director	Apr 16 '24	Sale	55.55	9,402	522,260	0	Apr 18 04:01 PM
Elghandour Rami	SEE REMARKS	Apr 01 '24	Sale	67.09	23,086	1,548,887	69,253	Apr 03 04:44 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 26 '24	Option Exercise	6.28	5,450	34,226	14,388	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 26 '24	Sale	69.11	5,450	376,648	8,938	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 22 '24	Option Exercise	6.28	20,000	125,600	50,303	Mar 26 08:52 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Mar 22 '24	Sale	70.18	41,365	2,903,066	8,938	Mar 26 08:52 PM
Carroll Jill	Director	Mar 21 '24	Sale	70.55	504,263	35,575,755	1,479,148	Mar 25 05:30 PM
Gilson Michelle	CHIEF FINANCIAL OFFICER	Mar 18 '24	Sale	69.34	6,825	473,255	9,485	Mar 18 08:49 PM
Ware Olivia C	Director	Mar 15 '24	Option Exercise	7.61	9,000	68,490	9,000	Mar 18 06:38 PM
Ware Olivia C	Director	Mar 15 '24	Sale	70.40	9,000	633,582	0	Mar 18 06:38 PM
Elghandour Rami	SEE REMARKS	Feb 12 '24	Sale	64.46	11,169	719,948	92,339	Feb 12 07:43 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 12 '24	Sale	64.46	2,967	191,251	30,303	Feb 12 07:46 PM
Elghandour Rami	SEE REMARKS	Feb 09 '24	Sale	63.40	13,886	880,340	103,508	Feb 12 07:43 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 09 '24	Sale	63.40	3,688	233,811	33,270	Feb 12 07:46 PM
Elghandour Rami	SEE REMARKS	Feb 08 '24	Sale	62.29	13,010	810,451	117,394	Feb 12 07:43 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 08 '24	Sale	62.29	3,456	215,290	36,958	Feb 12 07:46 PM
Heery Christopher	CHIEF MEDICAL OFFICER	Feb 07 '24	Option Exercise	0.00	22,555	0	40,414	Feb 09 04:08 PM
Elghandour Rami	SEE REMARKS	Feb 07 '24	Option Exercise	0.00	70,211	0	130,404	Feb 09 04:05 PM
Elghandour Rami	See Remarks	Jan 04 '24	Sale	55.27	29,073	1,606,804	60,193	Jan 08 04:02 PM
Gilson Michelle	Chief Financial Officer	Jan 04 '24	Sale	55.27	8,514	470,551	16,310	Jan 08 04:04 PM
Heery Christopher	Chief Medical Officer	Jan 04 '24	Sale	55.27	7,598	419,926	17,859	Jan 08 04:06 PM
Heery Christopher	Chief Medical Officer	Jan 03 '24	Option Exercise	0.00	16,519	0	25,457	Jan 04 07:32 PM
Elghandour Rami	See Remarks	Jan 03 '24	Option Exercise	0.00	53,097	0	89,266	Jan 04 07:29 PM
Heery Christopher	Chief Medical Officer	Dec 18 '23	Option Exercise	6.28	120,000	753,600	127,795	Dec 19 04:43 PM
Heery Christopher	Chief Medical Officer	Dec 18 '23	Sale	50.17	120,000	6,020,281	7,795	Dec 19 04:43 PM
Carroll Jill	Director	Dec 14 '23	Sale	49.13	504,263	24,774,441	1,983,411	Dec 18 04:47 PM
Heery Christopher	Chief Medical Officer	Aug 04 '23	Option Exercise	15.00	3,000	45,000	10,795	Aug 07 04:51 PM
Heery Christopher	Chief Medical Officer	Aug 04 '23	Sale	35.38	3,000	106,133	7,795	Aug 07 04:51 PM
Heery Christopher	Chief Medical Officer	Jul 03 '23	Option Exercise	15.00	3,000	45,000	10,795	Jul 05 08:06 PM
Heery Christopher	Chief Medical Officer	Jul 03 '23	Sale	31.75	3,000	95,246	7,795	Jul 05 08:06 PM
Carroll Jill	Director	Jun 01 '23	Sale	44.35	25,556	1,133,317	2,487,674	Jun 02 04:56 PM
Carroll Jill	Director	May 31 '23	Sale	41.50	315,164	13,079,306	2,513,230	Jun 02 04:56 PM
Elghandour Rami	See Remarks	May 31 '23	Sale	44.27	2,600	115,099	36,169	Jun 02 05:10 PM
Gilson Michelle	Chief Financial Officer	May 25 '23	Sale	42.77	6,000	256,616	9,485	May 25 08:21 PM
Gilson Michelle	Chief Financial Officer	May 24 '23	Sale	42.46	8,704	369,534	15,485	May 25 08:21 PM
Gilson Michelle	Chief Financial Officer	May 23 '23	Option Exercise	0.00	22,428	0	24,189	May 25 08:21 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	May 11 '23	Sale	45.01	1,012,833	45,589,317	1,658,780	May 15 06:16 PM
Carroll Jill	Director	May 11 '23	Sale	45.01	638,417	28,736,223	2,828,394	May 15 06:18 PM
Heery Christopher	Chief Medical Officer	May 10 '23	Sale	45.18	2,197	99,266	7,795	May 11 04:10 PM
Heery Christopher	Chief Medical Officer	May 09 '23	Sale	45.00	500	22,500	9,992	May 11 04:10 PM
Heery Christopher	Chief Medical Officer	May 05 '23	Sale	45.00	1,200	54,002	10,492	May 08 06:50 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

EFTR

eFFECTOR Therapeutics Inc

ACLX

Arcellx Inc

Upgrade your FINVIZ experience